Association between platelet reactivity and circulating platelet-derived microvesicles in XXXX with @entity1187 .

@entity1 @entity1187 @entity1423 @entity1397 @entity117 @entity11603 @entity8729 @entity17432 @entity22844 @entity857
Abstract @entity1423 ( @entity1423 ) to @entity1397 has been shown to increase the risk of cardiovascular events. Platelet-derived microvesicles (PMVs) may be prothrombotic and contribute to the risk of recurrent events observed in @entity1 with @entity1423 . However, PMVs may also serve as biomarkers and be used to assess platelet function. We investigated the association between platelet responses to @entity1397 (measured by whole blood impedance aggregometry) and circulating PMVs in @entity1 with @entity1187 ( @entity1187 ). Blood samples were obtained at discharge from 200 @entity1 with @entity1187 who had undergone percutaneous coronary intervention (PCI). All @entity1 were loaded with @entity117 and @entity1397 before PCI. @entity857 -induced whole blood impedance aggregometry and measurement of PMVs were performed. Cut-off values for @entity1423 and other reactivity (i.e. normal on-treatment reactivity, NPR and low on-treatment reactivity, LPR) to @entity1397 were set according to data from large prospective studies. We measured PMVs as phosphatidylserine and @entity17432 positive vesicles, together with @entity8729 or @entity11603 , using flow cytometry. @entity857 -induced platelet aggregation revealed that approximately 20% of @entity1 had @entity1423 . Levels of PMVs were almost two-fold higher in the @entity1423 group compared with @entity1 without @entity1423 (for both @entity17432 - and @entity8729 -positive PMVs, p   <   0.01). Furthermore, @entity1 with LPR to @entity1397 had significantly fewer PMVs exposing @entity8729 than @entity1 with @entity1423 or those with NPR to @entity1397 . @entity1 with @entity1423 during @entity1397 treatment have elevated levels of circulating PMVs, indicating ongoing platelet activation despite @entity1397 treatment. Moreover, in @entity1 with LPR to @entity1397 , circulating @entity22844 numbers are decreased. Taken together, our data suggest that PMVs are potential biomarkers of antiplatelet responses to @entity1397 . If PMVs also have prognostic value after, @entity1187 should be tested in future studies.
